Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vapaliximab

Next Previous
X
Search
Drug Profile

Vapaliximab

Alternative Names: BTT-1002; Huvap

Latest Information Update: 02 Mar 2017

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioTie Therapies; University of Cambridge; University of Turku
  • Developer BioTie Therapies
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Inflammation; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 24 Apr 2012 Vapaliximab is no longer licensed to Seikagaku Corporation in Japan, Taiwan, Singapore, Australia and New Zealand
  • 19 Jul 2004 This compound is still in active development - BIO 2004 Annual International Convention (BIO-2004)
  • 08 Jul 2003 The licensing agreement between BioTie Therapies and Seikagaku Corporation has taken effect

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top